Article
TAP Pharmaceutical to settle claims, pay $150 million
TAP Pharmaceutical Products agreed to settle claims that consumers and private insurers overpaid for the LHRH hormone analog leuprolide acetate (Lupron), according to a report in The Boston Globe.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Content
